{"id":"NCT00549939","sponsor":"Sanofi","briefTitle":"Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","officialTitle":"12-week, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy, Pharmacodynamic and Safety of 2 Doses of Alfuzosin (0.1 mg/kg/Day, 0.2 mg/kg/Day) in the Treatment of Children and Adolescents 2-16 Years With Elevated Detrusor Leak Point Pressure of Neuropathic Etiology Followed by a 40-week Open-label Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-10","primaryCompletion":"2009-03","completion":"2009-12","firstPosted":"2007-10-26","resultsPosted":"2011-02-08","lastUpdate":"2014-10-29"},"enrollment":172,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Neurogenic Urinary Bladder"],"interventions":[{"type":"DRUG","name":"Alfuzosin","otherNames":["SL770499"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Alfuzosin 0.1 mg/kg/day","type":"EXPERIMENTAL"},{"label":"Alfuzosin 0.2 mg/kg/day","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study was to evaluate the efficacy of Alfuzosin in comparison to Placebo on the detrusor Leak Point Pressure (LPP) in children and adolescents 2-16 years of age with elevated detrusor LPP of neuropathic etiology and detrusor LPP ≥ 40 cm H2O.\n\nSecondary objectives were:\n\n* To investigate the safety and tolerability of two doses of Alfuzosin in comparison to Placebo in children and adolescents,\n* To evaluate the effects of the two doses of Alfuzosin in comparison to Placebo on:\n\n  * Detrusor compliance,\n  * Urinary tract infection,\n* To investigate the pharmacokinetics of Alfuzosin (population kinetics),\n* To evaluate the 12-month long-term safety of Alfuzosin 0.1 mg/kg/day and 0.2 mg/kg/day.\n\nThe study consisted of 2 periods:\n\n* a 12-week double blind treatment period where patients were to receive either Alfuzosin 0.1 mg/kg/day or Alfuzosin 0.2 mg/kg/day or placebo then,\n* a 40-week open label extension treatment period where patients were to receive either Alfuzosin 0.1 mg/kg/day or Alfuzosin 0.2 mg/kg/day.","primaryOutcome":{"measure":"Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O","timeFrame":"12 weeks (double blind treatment period)","effectByArm":[{"arm":"Placebo","deltaMin":23,"sd":null},{"arm":"Alfuzosin 0.1 mg/kg/Day","deltaMin":23,"sd":null},{"arm":"Alfuzosin 0.2 mg/kg/Day","deltaMin":28,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"1.00"},{"comp":"OG000 vs OG002","p":"0.91"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":8},"locations":{"siteCount":18,"countries":["United States","Bulgaria","Canada","Estonia","France","Germany","India","Malaysia","Philippines","Poland","Portugal","Russia","Serbia","Singapore","Slovakia","Spain","Taiwan","Turkey (Türkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":83},"commonTop":["NASOPHARYNGITIS","DIARRHOEA","PYREXIA","URINARY TRACT INFECTION","CYSTITIS"]}}